917389-32-3

Basic information

• Product Name: LeterMovir
• Synonyms: AIC246;LeterMovir;(4S)-8-Fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic acid;4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-, (4S)-;Letermovir (AIC246)
• CAS NO: 917389-32-3
• Molecular Formula: C₂₉H₂₈F₄N₄O₄
• Molecular Weight: 572.5506328
• Mol File: 917389-32-3.mol

Chemical Properties

• Boiling Point: 706.5±70.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility: ≥57.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
• PKA: 4.00±0.10(Predicted)
• CAS DataBase Reference: LeterMovir(CAS DataBase Reference)
• NIST Chemistry Reference: LeterMovir(917389-32-3)
• EPA Substance Registry System: LeterMovir(917389-32-3)

Safety Data

• Hazardous Substances Data: 917389-32-3(Hazardous Substances Data)

Usage

Uses

Used in Antiviral Applications:
Letermovir is used as an antiviral agent for the treatment of CMV infection in immunocompromised individuals. It inhibits the activity of the cytomegalovirus terminus complex, thereby preventing the replication and spread of the virus.
Used in Immunocompromised Patient Care:
Letermovir is used in the healthcare industry as a treatment option for immunocompromised patients who are at a higher risk of developing CMV infection. By inhibiting the virus, Letermovir helps in managing and controlling the infection, reducing the severity of the symptoms and improving the overall health of the patients.

Upstream product

• 917389-21-0 methyl 2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-4-yl)acetate 
• 348-54-9 2-Fluoroaniline 
• 16588-75-3 2-methoxy-5-trifluoromethylphenyl isocyanate 
• 917389-24-3 N-(2-fluorophenyl)-N'-[2-methoxy-5-(trifluoromethyl)phenyl]urea 
• 65896-11-9 2-bromo-6-fluoroaniline 
• 791117-40-3 methyl 2-[8-fluoro-3-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl] acetate 
• 349-65-5 2-Methoxy-5-trifluoromethyl-aniline 
• 917389-23-2 3-(2-bromo-6-fluorophenyl)-1-[2-methoxy-5-(trifluoromethyl)phenyl]urea 
• 791116-51-3 (+/-)-{8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-trifluoromethyl-phenyl]-3,4-dihydro-quinazolin-4-yl}acetic acid 
• 917389-37-8 (R)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid 
• 917389-35-6 [(R)-8-fluoro-2-[4-(3-methoxy-phenyl)-piperazin-1-yl]-3-(2-methoxy-5-trifluoromethyl-phenyl)-3,4-dihydro-quinazolin-4-yl]-acetic acid methyl ester (2R,3R)-2,3-bis-(4-methyl-benzoyloxy)-succinic acid salt 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF AN INTERMEDIATE USED IN THE SYNTHESIS OF LETERMOVIR

Disclosed is an enantioselective process for the preparation of letermovir of formula (I) which comprises enantioselective addition of (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)ethanone (IV), catalysed by TiCl4 on the imine of formula III, to give intermediate V, which is hydrolysed to the acid of formula VI and subsequently cyclised in the presence of organic bases to give intermediate VII, from which letermovir is obtained with good yields and a high degree of enantioselection.

NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS

Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.

Access to Chiral Hydropyrimidines through Palladium-Catalyzed Asymmetric Allylic C?H Amination

A palladium-catalyzed asymmetric intramolecular allylic C?H amination controlled by a chiral phosphoramidite ligand was established for the preparation of various substituted chiral hydropyrimidinones, the precursors of hydropyrimidines, in high yields with high enantioselectivities. In particular, dienyl sodium N-sulfonyl amides bearing an arylethene-1-sulfonyl group underwent a sequential allylic C?H amination and intramolecular Diels–Alder (IMDA) reaction to produce chiral fused tricyclic tetrahydropyrimidinone frameworks in high yields and with high levels of stereoselectivity. Significantly, this method was used as the key step in an asymmetric synthesis of letermovir.

Asymmetric synthesis of letermovir using a novel phase-Transfer-catalyzed aza-michael reaction

The development of a concise asymmetric synthesis of the antiviral development candidate letermovir is reported, proceeding in 60% yield over a total of seven steps from commercially available materials. Key to the effectiveness of this process is a nove

DIHYDROQUINAZOLINE INHIBITORS OF VIRAL TERMINASE

The present invention relates to new dihydroquinazoline modulators of viral infection, pharmaceutical compositions thereof, and methods of use thereof.

SODIUM AND CALCIUM SALTS OF DIHYDROQUINAZOLINE DERIVATIVE AND USE THEREOF AS ANTIVIRAL AGENTS

The invention relates to sodium and calcium salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treatment and/or prophylaxis of virus infections and to the use thereof for producing drugs for use in methods of treatment and/or prophylaxis of diseases, more particularly the use thereof as antiviral agents, more particularly against cytomegaloviruses.

Salts of a dihydroquinazoline derivative

The invention relates to besylate and tosylate salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treating and/or preventing virus infections, and to the use thereof to produce drugs for use in treating and/or preventing diseases, in particular use as antiviral agents, in particular against cytomegaloviruses.

PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIVIRALLY ACTIVE DIHYDROQUINAZOLINE DERIVATIVE

The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination w

PROCESS FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS

The present invention is directed to a process for making Substituted Quinazoline Compounds of formula (I): which are useful for the treatment and prophylaxis of HCMV infection. The present invention is also directed to compounds that are useful as synthe

AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL FORMULATIONS THEREOF FOR ORAL ADMINISTRATION

The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30°C to 60°C, and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).